Cost-Effective Analysis of Ceftriaxone as Prophylactic Antibiotic in Caesarean Section: Single Dose Versus Multiple Dose

Authors

  • Bayu Pertiwi Fakultas Farmasi, Universitas Pancasila ,
  • Hesty Utami Ramadaniati Fakultas Farmasi, Universitas Pancasila ,
  • Prih Sarnianto Fakultas Farmasi, Universitas Pancasila ,
  • Dwirani Amelia Fakultas Farmasi, Universitas Pancasila ,

DOI:

https://doi.org/10.35814/jifi.v20i2.1084

Keywords:

Caesarean section, ceftriaxone, prophylactic antibiotic, surgical site infection

Abstract

The provision of single-dose prophylactic antibiotics within 30 to 60 minutes before caesarean has been highly recommended, yet its implementation in hospitals varies considerably. This research aimed to analyze the cost-effectiveness of prophylactic antibiotics given a single dose versus multiple doses during caesarean section surgery. A retrospective observational study with a crosssectional design involved pregnant women undergoing caesarean section and receiving a ceftriaxone single dose before surgery (Group 1) versus those receiving multiple ceftriaxone doses (Group 2). The study calculated direct medical costs (hospital perspective), with surgical site infection (SSI) as the effectiveness parameter. The chi-square test was used to compare SSI between the two groups. There were 806 patients (group 1) and A total of 250 patients (Group 2) met the inclusion criteria. Analysis of total cost revealed no significant difference between both groups (approximately IDR 13,000,000/patient), yet patients receiving prolonged Ceftriaxone were associated with significantly higher antibiotic costs (p-0.000). The study documented 1.2% SSI in Group 1 and 0.8% in Group 2 (p=0.742). Calculation of the incremental cost-effectiveness ratio found that an extra IDR 3,278,000 was needed to provide additional success to prevent SSI by administering multiple doses of ceftriaxone. In conclusion, a single dose prophylactic antibiotic provides comparable efficacy to a multiple-dose regimen, but at a lower cost.

References

Downloads

Published

2022-10-30

Issue

Vol. 20 No. 2 (2022): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.